Chatbot aims to close genetic testing gap for black cancer survivors

NCT ID NCT06073626

Recruiting now Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a chatbot to standard care to see which better helps Black cancer survivors learn about and request genetic testing for hereditary cancer. About 428 participants will be randomly assigned to either group. The goal is to reduce disparities in genetic testing and improve informed decision-making.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chatbot
What this could lead to: If successful, this could show that a chatbot is an effective way to increase genetic testing among Black cancer survivors, helping to reduce health disparities.
What could go wrong: This is an early-stage study focused on education and testing uptake, not a treatment. The chatbot may not significantly improve outcomes over usual care, and results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer hereditary neoplastic syndrome malignant pancreatic neoplasm ovarian cancer prostate cancer uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC TESTING HEREDITARY CANCER

Contacts and locations

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Rutgers Cancer Institute
RECRUITING

New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.